© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
December 03, 2021
Here are the top 5 biosimilar articles for the week of November 29, 2021.
December 02, 2021
December 01, 2021
November 30, 2021
November 29, 2021
November 28th 2021
By Skylar Jeremias
Karen van Caulil, PhD, president and CEO at Florida Alliance for Healthcare Value, discusses the difficulty her institution has had in getting providers and employers to switch to biosimilars.
November 27th 2021
By Sarfaraz K. Niazi, PhD
An expert on biotherapeutics recommends more science be applied to World Health Organization (WHO) biosimilar guideline revisions.
November 26th 2021
Here are the top 5 biosimilar articles for the week of November 22, 2021.
November 25th 2021
By Deana Ferreri, PhD
A study of trastuzumab biosimilars and the reference product (Herceptin) under control and stress conditions elucidated the value of machine learning.
November 24th 2021
By Tony Hagen
Authors of a new study estimated significant savings from biosimilars in Ontario based on deep price discounts and mandatory switching programs.
November 23rd 2021
Authors of a review discuss barriers to insulin access and potential solutions as the 100-year anniversary of the drug's first use for diabetes gets closer.
November 22nd 2021
Progression-free survival (PFS) was improved for patients with epidermal growth factor receptor–mutated nonsquamous non–small cell lung cancer who were treated with PD-1 and antivascularization therapy.
November 21st 2021
The utilization rates for biosimilars in community oncology have been much higher than for other disease categories and are only expected to rise, says Steven Yates, MD.
November 20th 2021
Stakeholder education programs and robust data on clinical studies are key to building patient and provider support for biosimilars, according to a new whitepaper.
November 19th 2021
Here are the top 5 biosimilar articles for the week of November 15, 2021.